TDP-43 normally resides in the nucleus, where it has several roles in maintaining neuronal health and function. In most cases of ALS, the protein leaves the nucleus and aggregates in the cytoplasm. The research group had previously shown that sudden stress can prevent TDP-43 from forming the pairs or small groups in which it normally operates, causing individual molecules to be re-exported from the nucleus as dysfunctional material. The team’s new experiments traced what happens when these unpaired TDP-43 molecules enter the cytoplasm. They physically interact with TBK1, a sensor protein known to activate autophagy and one whose gene mutations can cause inherited ALS.

Autophagy is the process by which faulty proteins are collected in small vesicles and digested. When Sakai inhibited that process, the elimination of TDP-43 was not blocked in his experiments, leading the researchers to investigate a parallel mechanism. TBK1 also activates a signal mediated by interferon beta that can be perceived by the neuron producing it and by neighboring cells. Neurons that received the signal increased production of the immunoproteasome, a protein-degrading system that normally helps immune cells disassemble virus components and display peptide fragments on their surfaces. In the experimental models, increased immunoproteasome activity broke down TDP-43 before it aggregated. The finding shows that motor neurons can deploy this system in response to abnormal proteins, in addition to its better-established role in immune cells during viral infection.

Evidence for the pathway came from multiple experimental systems. Cultured neurons and human stem cell-derived motor neurons were used to examine the sequence connecting TDP-43 with TBK1, interferon beta and immunoproteasome activity, while mouse experiments provided additional support. The researchers also analyzed spinal-cord samples donated after death by people with ALS. The receptor for the interferon-beta signal was present in significantly lower quantities in motor neurons from the ALS samples than in samples from people without ALS. This tissue-level difference is an association: the study did not establish that reduced receptor abundance causes TDP-43 accumulation or ALS. Cultured-cell and mouse findings also cannot by themselves demonstrate clinical benefit in patients.

The researchers described the pathway as a possible therapeutic avenue, but they cautioned that directly administering interferon beta does not appear practical for ALS. Interon beta has been used in treatments for other conditions, but it triggers many biological responses, and its severe side effects cannot be ignored. Yamanaka said the group’s next objective is to identify other compounds that can activate the immunoproteasome in motor neurons. Sakai said the pathway’s true therapeutic potential remains to be established. The study therefore identifies a mechanism for further investigation rather than a proven intervention: the reported findings come from neuronal cultures, mice and postmortem human tissue, and no treatment efficacy or safety was evaluated in people with ALS.

Subject of Research: Mechanisms of TDP-43 clearance and immunoproteasome activation in ALS models

Article Title: A new path(way) for ALS research opens

Article References: A new path(way) for ALS research opens. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: ALS, TDP-43, TBK1, interferon beta, immunoproteasome, motor neurons, protein aggregation, stem cell-derived neurons, mouse models, Nagoya University, path, research

The findings suggest that targeting this pathway could help limit damage to healthy lung tissue during cancer radiotherapy, although the approach has not been tested as a treatment in patients. The study appeared in Nature Communications on October 20, 2026, under the title “Type I IFN promotes ILC2-to-ILC1 plasticity in pre-clinical radiation-induced lung injury.” Radiation can be lifesaving in cancer treatment, but healthy lung tissue exposed during radiotherapy may develop severe and lasting damage.

City of Hope reported that as many as 70% of people diagnosed with lung cancer undergo radiation at some point in their treatment. Following injury, as many as 20% of patients may experience debilitating breathing difficulties and reduced quality of life, with some becoming dependent on supplemental oxygen. The new study does not establish that blocking interferon-beta can prevent these outcomes in people.

Instead, it identifies a cellular and molecular mechanism in a mouse model of radiation-induced lung injury and shows that interrupting the pathway can lessen pulmonary damage in experimental animals. Corresponding author Heather McGee, M.D., Ph.D., an assistant professor in City of Hope’s departments of radiation oncology and immuno-oncology, led the investigation with first author Jaeho Kim, M.D., Ph.D., a radiation oncology postdoctoral fellow. The team developed a mouse model of radiation injury to the lung and used immune-cell tracking methods to examine how radiation changed innate lymphoid cells, or ILCs.

These comparatively rare immune cells were the focus because the researchers wanted to determine whether they changed identity or function after irradiation. The experiments addressed three linked questions: whether radiation altered the ILC population, which signal drove the alteration, and whether blocking that signal could reduce lung damage. The first result was a pronounced transformation within the innate lymphoid cell population.

ILC2 cells normally help protect the lung from damage, whereas ILC1 cells promote inflammation that can injure healthy tissue. After radiation exposure, the investigators observed ILC2 cells adopt characteristics associated with the inflammatory ILC1 state. They described this transition as ILC2-to-ILC1 plasticity, meaning that the cells did not simply remain in one functional identity but changed their state in response to radiation.

The altered cells were linked to harmful inflammation in the lung. This result extends the study’s focus beyond better-known immune cells, including T cells, and points to a specific population through which radiation can affect lung tissue. The second finding identified interferon-beta as the molecular signal driving the transition.

Radiation increased levels of this type I interferon signaling protein, while experimental disruption of its pathway reduced the shift of ILC2 cells toward the inflammatory ILC1 state. McGee described the mechanism as comparable to a player switching teams: radiation-induced interferon-beta could move innate lymphoid cells away from a protective role and toward one that promotes inflammation. The finding provides a mechanistic link rather than only an association.

In the experimental system, a defined signaling event was connected to a change in cellular identity and function, and that function was connected to damage in healthy lung tissue. The researchers also examined human innate lymphoid cells to determine whether the biological changes seen in the mouse model had a counterpart in human cells. Those experiments produced similar changes, indicating that the reprogramming mechanism was not confined to the mouse cells used for the lung-injury experiments.

Human-cell findings support biological relevance, but they do not demonstrate that modifying interferon-beta signaling will be safe or effective in patients receiving radiation. The source described the pathway intervention as a potential strategy, and no human treatment trial or clinical efficacy result was reported. Its effects on radiation-related lung injury therefore remain a preclinical possibility rather than an established clinical application.

For the third set of experiments, the team tested whether blocking interferon-beta signaling during radiation could protect the lungs. In mice, disrupting the pathway reduced inflammation, limited lung injury and decreased fibrosis, the scarring process that can permanently damage healthy lung tissue. These outcomes were measured in an experimental model of radiation-induced pulmonary injury, not among people with cancer.

The result nevertheless identifies a focused point of intervention. That distinction is central to the study’s proposal: the biological pathway associated with lung harm was interrupted while radiation was being delivered. The clinical importance of the work lies in the potentially persistent consequences of radiation injury.

Healthy lung tissue exposed during radiotherapy can become inflamed and scarred, leading to breathing difficulty, reduced quality of life and limits on future cancer treatment options. City of Hope noted that some affected patients become tethered to heavy oxygen tanks. Kim said the findings suggest that high levels of interferon-beta contribute to radiation-induced lung damage and that blocking the signaling pathway could offer a potential way to reduce this side effect.

If the approach proves effective in people, it could protect lung tissue and perhaps expand radiation options for people with chronic lung conditions such as chronic obstructive pulmonary disease, or allow more aggressive radiation treatment when needed. Those possibilities remain conditional and untested. The researchers did not merely document inflammation and lung damage after irradiation.

They showed that innate lymphoid cells changed state, identified increased interferon-beta signaling as the driver of that change, observed related biological changes in human ILCs, and found that disrupting the pathway reduced inflammation, injury and fibrosis in mice. The design supports the conclusion that interferon-beta signaling contributes causally to radiation-associated lung damage within the experimental model. It does not establish how the same pathway behaves in the full complexity of a person receiving cancer treatment, nor whether targeted blockade could produce benefits without other immune effects.

City of Hope, which described the work as a potential route to new treatments that protect healthy lung tissue, is part of a broader cancer research and treatment organization. The project was funded by grants from the National Cancer Institute, the National Institutes of Health and the Veterans Affairs Office of Research and Development. The release stated that its content was solely the responsibility of the authors and did not necessarily represent the official views of the NIH.

Because the investigation is preclinical, the result should not be interpreted as evidence of a clinical therapy. What it establishes is a testable mechanism: radiation-induced interferon-beta signaling appears to convert lung-protective ILC2 cells into inflammatory ILC1 cells, and interrupting that pathway reduced radiation-related lung harm in mice. Whether the same selective strategy can safely and effectively translate to human radiotherapy remains to be established.

Subject of Research: Preclinical research on interferon-beta-driven immune-cell reprogramming in radiation-induced lung injury

Article Title: New study identifies immune trigger behind radiation-related lung damage

Article References: New study identifies immune trigger behind radiation-related lung damage. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: radiation-induced lung injury, interferon-beta, innate lymphoid cells, ILC2-to-ILC1 plasticity, pulmonary fibrosis, radiotherapy, lung inflammation, cancer treatment, identifies, immune, trigger, behind

On admission, the patient exhibited fever of 38.3 °C, leukocytosis at 16,200/μL, elevated lactate dehydrogenase at 701 IU/L, and a markedly elevated C-reactive protein level of 27.07 mg/dL. Metastatic liver tumors and infection were suspected, prompting hospitalization for antibiotic treatment. However, blood cultures obtained before treatment initiation were negative, and antibiotic therapy failed to improve either the fever or the CRP elevation. His condition deteriorated rapidly, with persistent fever, worsening ascites, and a decline in performance status from 0 to 3. Planned liver biopsy and endoscopic procedures were canceled due to his declining condition, and ascitic cytology showed no malignancy. Despite the lack of histological confirmation, magnetic resonance imaging showed T1 hyperintense liver lesions, and 5-S-cysteinyldopa was elevated at 124 nmol/L, indicating metastatic melanoma.

Nivolumab treatment was initiated, resulting in rapid improvement. The fever resolved within days, and CRP promptly decreased to below 5 mg/dL by day 10, indicating a tumor-related inflammatory response rather than infection. After treatment initiation, BRAF testing revealed a V600E mutation, but nivolumab was continued given the clear clinical response. Three months post-treatment, the hepatic lesions became indistinct, and the patient’s performance status returned to 0. He has shown sustained response to nivolumab for over two years, monitored with non-contrast CT due to mild chronic kidney disease.

Malignant melanoma is a skin cancer with a high risk of recurrence and metastasis. The interval between initial treatment and subsequent recurrence or metastasis typically shortens with disease progression. In a large Duke University cohort of 7,104 patients, only 168 patients — 2.4 percent — developed their first recurrence after a 10-year disease-free interval. The majority of these patients had early-stage disease, with 92.9 percent at stage I and 6.5 percent at stage II, whereas only one patient, 0.6 percent, initially presented with stage III disease. These findings indicate that late first relapse more than 10 years after initial treatment is uncommon, and that such relapse is particularly rare in patients who initially present with stage III melanoma. Nevertheless, this patient developed hepatic metastases 11 years after surgery despite initially having stage III disease, highlighting that metastatic melanoma should remain in the differential diagnosis when evaluating new hepatic lesions even after a prolonged disease-free interval, including in patients with initially advanced-stage disease.

The mechanisms underlying late recurrence of melanoma remain incompletely understood, but long-term tumor dormancy followed by disruption of immune control or tumor immune escape has been proposed. Reschke and colleagues suggested that melanoma cells may detach from the primary tumor and disseminate via lymphatic or hematogenous routes several decades before distant metastases become clinically apparent. They discussed tumor dormancy as a multifactorial process involving immune-mediated growth control, cell-cycle arrest with reduced metabolic activity, and angiogenic regulation. They also proposed that individual immune surveillance may control residual melanoma cells for more than a decade, whereas advanced age and increasing comorbidities may disturb the immunological balance and contribute to overt recurrence.

Tissue-resident memory T cells may be one component of this immune-mediated dormancy. Plunkett and colleagues reviewed evidence that TRM can maintain melanoma in a state of immune-mediated equilibrium, preventing progression to macroscopic disease. In preclinical models, TRM surveilled skin regions containing melanoma cells and mediated protection in a TNF-α-dependent manner. However, the mechanisms by which occult melanoma subsequently becomes clinically overt remain unclear. Plunkett and colleagues described a possible immune-escape mechanism involving CD8-positive T cells and the PD-1/PD-L1 axis. In this model, engagement of PD-1 on CD8-positive T cells by tumor-expressed PD-L1 attenuates T-cell receptor signaling, proliferation, and cytotoxicity, thereby suppressing anti-tumor immune responses. This PD-1/PD-L1-mediated impairment of CD8-positive T-cell activity may represent one mechanism by which dormant melanoma cells escape long-term immune surveillance and eventually progress to clinically apparent recurrence.

In the present case, the three-year course of adjuvant intralesional interferon-β therapy may have been one of several factors contributing to prolonged immune-mediated tumor control, although its role cannot be determined. Conversely, age-related alterations in immune surveillance may have disrupted this equilibrium and contributed to the abrupt clinical manifestation of recurrence. The interplay between long-standing immune control and eventual immune escape remains a central question in understanding why some melanomas reappear after a decade or more of dormancy while others never do.

In this case, MRI played a pivotal role in diagnosing liver metastasis. Malignant melanoma often exhibits hyperintense signals in T1-weighted MRI images, a critical characteristic finding under challenging histological confirmation. MRI can be especially useful in such cases, where biopsy or other tissue-based diagnostic methods are not feasible. The combination of T1 hyperintense lesions and elevated 5-S-cysteinyldopa provided sufficient diagnostic confidence to initiate treatment without histological confirmation, a decision that proved decisive given the patient’s rapidly declining condition.

Despite liver metastases — a factor associated with diminished clinical benefit from immune checkpoint blockade — this patient showed a rapid and sustained response to nivolumab. If late relapse in this case reflected immune escape through mechanisms such as those discussed by Plunkett and colleagues, restoring antitumor immunity via PD-1 blockade could be biologically plausible and may have contributed to the marked response observed. However, whether late first relapse is associated with enhanced sensitivity to immune checkpoint inhibitors remains uncertain. The efficacy of immune checkpoint inhibitors for late recurrence in ICI-naïve patients has not been well characterized; in this regard, further case accumulation is required to better define benefit predictors.

This case underscores several important clinical lessons. First, metastatic melanoma should remain in the differential diagnosis for new hepatic lesions even after a prolonged disease-free interval, including in patients with initially advanced-stage disease. Second, MRI characteristics of melanoma metastases can be diagnostically decisive when tissue confirmation is not feasible. Third, the remarkable and sustained response to nivolumab in this patient — despite liver metastases typically being associated with diminished immunotherapy benefit — suggests that the biology of late recurrence may differ fundamentally from that of early metastatic disease, potentially reflecting a tumor that has been held in check by immune surveillance for over a decade before escaping through PD-1/PD-L1-mediated mechanisms that nivolumab can reverse.

Subject of Research: Late liver metastasis recurrence of malignant melanoma and its treatment with the PD-1 inhibitor nivolumab

Article Title: Remarkable effect of nivolumab on late liver metastasis recurrence in advanced malignant melanoma

Article References: Fukuizumi, S., Kado, S., Ando, T., Sato, A., Kamiya, K., Maekawa, T., Ohtsuki, M., & Komine, M. (2026). Remarkable effect of nivolumab on late liver metastasis recurrence in advanced malignant melanoma. Journal of Cutaneous Immunology and Allergy, 9, Article 16775. https://doi.org/10.3389/jcia.2026.16775

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.16775

Keywords: melanoma, nivolumab, liver metastasis, late recurrence, immune checkpoint inhibitor, PD-1, tumor dormancy, tissue-resident memory T cells, MRI, interferon-beta, immunotherapy, case report

The research, led by Leonardo Palazzo and colleagues at the IRCCS San Raffaele Scientific Institute in Milan, drew on the Italian MS Registry, a nationwide repository of clinical data from people living with multiple sclerosis across the country. The team focused on patients with relapsing-remitting disease who had been treated for at least five years with one of four so-called platform therapies: the oral agents dimethyl fumarate and teriflunomide, and the injectable treatments interferon beta and glatiramer acetate. These drugs represent the long-standing backbone of first-line MS care, prescribed to hundreds of thousands of patients worldwide, yet head-to-head evidence on their effects against relapse-independent progression has remained strikingly thin.

Defining PIRA precisely is a technical challenge that has occupied the field in recent years. In this study, the investigators adopted a stringent operational definition: a confirmed worsening of disability on the Expanded Disability Status Scale that persisted for at least twelve months and occurred in the complete absence of any relapse during the relevant window. This twelve-month confirmation requirement helps filter out transient fluctuations in neurological function that can follow infections, fatigue, or heat, ensuring that the events counted as PIRA reflect genuine, sustained accumulation of impairment rather than temporary pseudoexacerbations.

From an initial pool of 1,910 eligible patients, the researchers constructed carefully balanced comparison groups using propensity score matching, a statistical technique that pairs treated individuals who share similar baseline characteristics such as age, sex, disease duration, and prior treatment history. Matching was performed separately for each drug comparison, yielding 174 matched pairs of dimethyl fumarate versus teriflunomide users and 404 matched pairs of interferon beta versus glatiramer acetate users. This design approximates the conditions of a randomized trial in a real-world setting, where treatment assignment is driven by clinical judgment rather than a protocol, and it helps reduce the confounding that typically plagues observational comparisons of therapies.

The statistical machinery applied to these matched cohorts was correspondingly rigorous. Negative binomial regression was used to model the cumulative number of PIRA events in each group, while Cox proportional hazards models estimated the time to a patient’s first PIRA event. Both approaches are standard tools in survival and event-count analysis, and their convergence strengthens the reliability of the findings. Across every comparison, the confidence intervals for the risk ratios and hazard ratios comfortably spanned the null value of one, indicating no statistically detectable difference between the therapies under study.

Specifically, teriflunomide-treated patients showed a cumulative PIRA risk ratio of 0.82 relative to those on dimethyl fumarate, with a 95 percent confidence interval of 0.47 to 1.40, and a hazard ratio of 0.81 for time to first event, with a confidence interval of 0.47 to 1.37. In the injectable comparison, glatiramer acetate versus interferon beta produced a risk ratio of 1.04 and a hazard ratio of 0.86, both similarly non-significant. When the investigators pooled the oral and injectable cohorts into a broader class-level comparison, the results again revealed no meaningful divergence, with a risk ratio of 0.79 and a hazard ratio of 1.06. In plain terms, none of the four platform drugs demonstrated a measurable advantage in shielding patients from relapse-independent disability accumulation.

The significance of this null result extends beyond the four drugs themselves. PIRA has emerged as a central concept in modern MS research because pooled analyses of clinical trial data have suggested that the majority of confirmed disability worsening in treated relapsing patients is, in fact, relapse-independent. Landmark work published in JAMA Neurology in 2020 estimated that relapse-independent progression contributes substantially to overall disability accumulation in typical relapsing disease, and subsequent cohort studies have confirmed that PIRA begins early, sometimes even after a first demyelinating event, and predicts long-term disability outcomes. If the inflammatory attacks are being controlled but patients continue to worsen silently, then understanding which therapies, if any, can modify this process becomes a question of enormous clinical weight.

The biological substrate of PIRA is thought to lie in mechanisms that conventional anti-inflammatory drugs reach only imperfectly: compartmentalized inflammation within the central nervous system, smoldering lesions with slowly expanding rims of microglial activation, meningeal inflammatory aggregates, diffuse gray matter damage, and progressive neurodegeneration that unfolds independently of peripheral immune attacks. Platform therapies such as interferon beta, glatiramer acetate, dimethyl fumarate, and teriflunomide were all developed primarily as modulators of peripheral immune activity, and the new findings are consistent with the idea that their shared mechanism of action leaves the smoldering intrathecal disease process largely untouched. Whether higher-efficacy agents, such as B-cell-depleting antibodies or potent immunosuppressants, offer better protection against PIRA remains an active area of investigation, with recent observational studies in Swiss and other cohorts beginning to explore these comparisons.

For clinicians and patients, the practical message of the Milan study is one of reassurance and clarity in therapeutic decision-making. Because the platform therapies appear equivalent with respect to PIRA risk, the choice among them can legitimately be guided by other considerations: safety profiles, tolerability, monitoring requirements, pregnancy planning, comorbidities, patient preference, and cost. Dimethyl fumarate requires regular lymphocyte and renal function monitoring; teriflunomide carries teratogenic risk and demands careful contraception counseling; interferon beta produces flu-like side effects and injection-site reactions; glatiramer acetate is generally well tolerated but demands frequent injections. None of these trade-offs, the study suggests, is offset by a differential ability to prevent silent progression.

The authors are careful to acknowledge the inherent limits of their design. Retrospective registry data, however carefully matched, cannot eliminate all confounding, and the five-year minimum treatment requirement may select for patients with milder disease courses who tolerate their therapy well. The confidence intervals, while centered near the null, are not narrow enough to exclude moderate differences between drugs, and the number of matched pairs in the oral comparison was comparatively modest. Nonetheless, the study represents one of the most direct real-world examinations of platform therapy effects on PIRA to date, and its conclusions align with a growing consensus, reflected in recent efforts to standardize PIRA definitions across the field, that relapse-independent progression is a distinct therapeutic target. As the MS treatment landscape shifts toward early use of high-efficacy agents, this work provides a sober benchmark: the older, gentler drugs, whatever their virtues, appear to stand shoulder to shoulder when it comes to the quiet accumulation of disability that no relapse ever announces.

Subject of Research: Comparative incidence of progression independent of relapse activity (PIRA) under platform disease-modifying therapies in relapsing-remitting multiple sclerosis

Article Title: Incidence of Progression Independent of Relapse Activity (PIRA) under platform disease-modifying treatment in multiple sclerosis

Article References: Palazzo, L., Clarelli, F., Giordano, A., Ferré, L., Moiola, L., Rocca, M. A., Esposito, F., Filippi, M., Clinical SanRaf MS Study Group, Missaglia, M., Visentin, G., Guido, G., Marino, V., De Simone, A., Viti, V., Zanetta, C., Margoni, M., Guerrieri, S., Petza, E., … Rossi, L. (2026). Incidence of Progression Independent of Relapse Activity (PIRA) under platform disease-modifying treatment in multiple sclerosis. Journal of Neurology, 273(10), Article 640. https://doi.org/10.1007/s00415-026-14171-8

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14171-8

Keywords: multiple sclerosis, PIRA, disease-modifying therapy, dimethyl fumarate, teriflunomide, interferon beta, glatiramer acetate, disability progression, Italian MS Registry, propensity score matching, relapsing-remitting multiple sclerosis, neuroimmunology